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Abstract: The importance of medication adherence in sustaining control of schizophrenic 
symptoms has generated a great deal of interest in comparing levels of treatment adherence 
with different antipsychotic agents. However, the bulk of the research has yielded results 
that are often inconsistent. In this prospective, observational study, we assessed the measure-
ment properties of 3 commonly used, pharmacy-based measures of treatment adherence with 
antipsychotic agents in schizophrenia using data from the Veterans Health Administration 
during 2000 to 2005. Patients were selected if they were on antipsychotics and diagnosed with 
schizophrenia (N = 18,425). A gap of 30 days (with no filled index medication) was used to 
define discontinuation of treatment as well as medication “episodes,” or the number of times 
a patient returned to the same index agent after discontinuation of treatment within a 1-year 
period. The study found that the 3 existing measures differed in their approaches in measuring 
treatment adherence, suggesting that studies using these different measures would generate dif-
ferent levels of treatment adherence across antipsychotic agents. Considering the measurement 
problems associated with each existing approach, we offered a new, medication episode-specific 
approach, which would provide a fairer comparison of the levels of treatment adherence across 
different antipsychotic agents.
Keywords: medication adherence, antipsychotic agents, schizophrenia
Introduction
Prior studies have demonstrated the efficacy and effectiveness of both typical 
(first-generation) and atypical (second-generation) antipsychotic agents in reducing 
schizophrenic symptoms.1,2 However, the likelihood of sustaining control of schizo-
phrenic symptoms depends on treatment adherence with antipsychotic agents by the 
patients.3,4 The importance of sustained medication treatment in the management of 
schizophrenia, coupled with known differential side effects associated with typical 
and atypical antipsychotic agents,5–8 has generated a lot of interest in the development 
of pharmacy-based measures to compare the levels of treatment adherence across 
different antipsychotic agents.9–17
In comparing treatment adherence with antipsychotic agents, there are 3 commonly 
used, pharmacy-based measures. Treatment persistence (TP) measures the length of time 
from the initiation of the index drug to the discontinuation of medication treatment as 
defined by a gap 30 days.18 This measure considers only the first medication “episode,” 
or the number of times a patient returned to the same index drug after discontinuation of 
medication treatment within 1 year, and does not take into account medication episodes 
beyond the first gap (or discontinuation of the medication). Medication possession Neuropsychiatric Disease and Treatment 2009:5 492
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ratio (MPR), on the other hand, measures the length of time 
or number of days on the index drug during a specified 1-year 
period.19,20 Unlike TP, MPR takes into account all medication 
“episodes” of the same drug but ignores the size of the gaps 
between medication episodes.” Finally, medication compli-
ance also measures the length of time on the medication 
using all medication “episodes” during 1 year. But unlike 
MPR, this approach takes into account the size of the gaps, 
ie, using 30 days to define medication discontinuation.21 
Since patients who came back to the same antipsychotic agent 
for a second or third time within 1 year may represent more 
complicated cases, treatment persistence considering only 
the first medication episodes while excluding subsequent 
ones is likely to yield biased results disfavoring antipsychotic 
agents with more patients having 2 medication episodes. 
Similarly, while MPR and medication compliance incorpo-
rate all medication episodes within 1 year, these measures 
do not differentiate patients with one vs multiple medica-
tion episodes. Patients with different number of medication 
episodes may differ in the levels of treatment adherence with 
antipsychotic agents.
In this prospective, observational study, we used existing 
data from the Veterans Health Administration (VA), the 
largest integrated health care system in the United States, 
during fiscal years 2000 to 2005 to assess the extent to which 
different measurement properties associated with each of the 
3 commonly used, pharmacy-based measures contributed to 
the inconsistent findings in the literature regarding the levels 
of treatment adherence with antipsychotic agents in schizo-
phrenia. Considering that there are measurement problems 
associated with each of the existing 3 measures of treatment 
adherence, in this study, we also provided a new “episode-
specific” approach to measuring treatment adherence that 
will provide a fairer comparison of the levels of treatment 
adherence across different antipsychotic agents.
Research design
The study used two existing databases from the Veterans 
Health Administration (VA): (1) pharmacy data from the VA 
National Pharmacy Benefits Management Program (PBM) 
and (2) VA national administrative data. The VA is the largest 
integrated health care system in the US, with approximately 
4.2 million enrollees and about 5% of the total US market 
share for hospital services. The VA administrative data con-
sist of an outpatient file, which provides information system 
about all outpatient clinic visits in the VA, and an inpatient 
file, which provides medical information about all discharges 
from VA inpatient settings, including ICD-9-CM codes 
representing admitting and discharge diagnoses.22 Pharmacy 
data came from the VA National Drug Formulary, which 
were automated uniformly throughout the VA system, and 
were updated monthly. The national pharmacy data consist 
of extensive prescription information for all VA patients who 
obtain their prescriptions in the VA system. This centralized 
database provides comprehensive prescription information: 
medication class, dose, dates of issues, fills, refills, and dis-
penses, quantity of pills dispensed, and number of days of 
medication dispensed. At the time of the study, the veterans 
enrolled in the VA were entitled to medications at no charge 
or with a US$7.00 co-payment. The economic incentive for 
veterans is almost always to obtain medications through 
VA medical centers rather than from other systems of care. 
This system allows for tracking almost all antipsychotic 
medications, whereas in other civilian systems this might 
be extremely difficult given multiple sources for initial and 
refill prescriptions such as pharmacy chains.
Patients were selected into the study by the following 
steps. First, using VA pharmacy data from 10/1/2001 
(October 1, 2001) through 3/31/2005 (March 31, 2005), 
we used a floating-date approach in identifying patients 
who “initiated” any of the eight selected antipsychotic 
agents, the most frequently prescribed agents in the VA. 
In other words, we selected patients with the first record 
of the index agent following at least 6 months with 
no record of the index agent. We also reserved 1 year 
following the initiation of the index agent for purposes 
of calculating treatment adherence. Therefore, during 
10/1/2001 and 3/31/2005, patients could initiate any of the 
selected antipsychotic agents at any time between 4/1/2002 
(the earliest possible dates for initiation due to the required 
prior 6-month clean period) and 4/1/2004 (the last possible 
dates for initiation due to the reserved 1 year for measuring 
treatment adherence). Second, to increase specificity, 
we further merged the pharmacy data with inpatient and 
outpatient data. Among the initiators of antipsychotic agents, 
we selected only those with 1 inpatient or 2 outpatient 
ICD-9-CM codes (7 days apart) of schizophrenia during 
10/1/1999 to 9/30/2002.
All 3 existing measures of medication adherence were 
calculated across eight antipsychotic agents. MPR was simply 
measured by the length of time a patient was on any index 
drugs during the 1-year post-initiation period. Both treatment 
persistence and medication compliance were measured as 
the length of time a patient was continuously on any antipsy-
chotic agents included in the study until a gap of 30 days 
with no filled index agent. In this study, a gap of 30 days Neuropsychiatric Disease and Treatment 2009:5 493
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with no filled index agent was used to define discontinuation of 
treatment with the index drug as well as “medication episodes” 
or the number of times a patient had a medication record of 
the same index drug within a 1-year period.
Finally, we calculated a new medication episode-specific 
approach in which we not only incorporated all medication 
episodes, but also distinguished patients with a different 
number of medication episodes. More specifically, we mea-
sured treatment adherence with the index antipsychotic agent 
separately among patients with 1, 2, and 3 or more medication 
episodes. This medication episode-specific approach adjusted 
for the possible biases resulting from differential proportion 
of patients with multiple medication episodes across various 
antipsychotic agents.
Results
Patients eligible for the study were predominantly male 
(94.3%) and single (81.1%) with a mean age of 51.0 
(SD = 10.7) (Table 1). They were more likely to be white 
(48.1%) and African-American (32.4%), with about 13% 
being “others” and 7% being Hispanics. Overall, the study sub-
jects had a mean of 4.1 (SD = 2.4) comorbid conditions, with 
a mean of 2.2 (SD = 1.2) comorbid mental and 1.8 (SD = 1.9) 
comorbid medical conditions. In the 6 months prior to the 
initiation of the index drug, 52.9%, 42.9%, and 12.4%, had 
prior use of antidepressants, anxiolytics, and mood stabilizers, 
respectively, and as high as 96.3% of the study subjects 
had at least 1 psychiatric-related outpatient visit and about 
32.3% had at least 1 psychiatric-related hospitalization.
Consistent with our earlier study findings,23 a significant 
number of schizophrenia patients included in the study 
had 1 medication episodes within a specified 1-year study 
period (Table 2), suggesting that patients came back to the 
same index antipsychotic agent for a second or third or 
more times after a gap of 30 days with no index agent. 
Moreover, the proportion of patients with multiple medica-
tion episodes tended to vary across various antipsychotic 
agents, especially among the atypical antipsychotic agents. 
As reported in Table 2, the percentage of patients having 
2 medication episodes ranged from 16.0% for olanzapine 
to 15.0% for risperidone, 14.5% for quetiapine, 10.5% for 
ziprasidone, and 8% for clozapine. Similarly, the percentage 
of patients having 3 medication episodes ranged from 4% 
for risperidone, 3.9% for olanzapine, 3.3% for quetiapine, 
and 2.6% for clozapine to 2.0% for ziprasidone. However, 
this pattern was not observed among the 3 typical agents, 
which had very similar percentages of patients with multiple 
medication records.
Table 1 Patient characteristics (N = 18,425)
Sociodemographic characteristics 
(2002)
Mean + SD %
Age, years 51.0 ± 10.7
Age groups, %:
  44 26.1
  45–49 21.8
  50–54 24.5
  55–59 11.5
  60 16.1
Male, % 94.3
Race, %
  White 48.1
  Black 32.4
  hispanic 6.9
  Others 12.7
Married, % 19.9
Clinical characteristics
Number of comorbid conditions  
(2 years prior to initiation)
  Total (mean + sD) 4.04 ± 2.4
  Mental (mean ± sD) 2.23 ± 1.2
  Physical (mean ± sD) 1.82 ± 1.9
Other clinical characteristics  
(6 months prior to initiation)
Prior use of antidepressants, % 52.9
Prior use of mood stabilizers, % 12.4
Prior use of anxiolytics, % 42.9
Prior use of clozapine, % 2.4
% with at least one outpatient 
 non-psychiatric visit
95.4
% with at least one outpatient  
psychiatric visit
96.3
% with at least one psychiatric  
hospitalization
32.3
% with at least one non-psychiatric 
hospitalization
15.9
Table 3 presents the results based on the 3 conventional 
approaches to measuring medication adherence. Treat-
ment persistence, which took into account only the first 
medication episode, is highlighted by 3 shaded columns in 
Table 3. The results based on this measure indicated that 
patients who initiated atypical agents were generally more 
adherent than those who initiated typical agents as exempli-
fied by longer days remained on the index drug following 
initiation until a gap of 30 days. Levels of treatment 
persistence also varied within each class of antipsychotic 
agents. Between 10/1/2002 and 3/31/2005, among the Neuropsychiatric Disease and Treatment 2009:5 494
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atypical agents, as expected, patients who initiated on 
clozapine were most adherent (255 days), followed by those 
initiated on quetiapine (186 days), ziprasidone (172 days), 
olanzapine (171 days), and risperidone (168 days). Among 
the typical agents, patients initiated on perphenazine were 
most adherent (169 days) and those initiated on haloperidol 
were least adherence (124 days). It is interesting to note that 
treatment persistence with perphenazine was equivalent to 
several atypical agents such as ziprasidone, olanzapine, and 
risperidone.
The last 2 columns of  Table 3 also present the results 
based on the other 2 conventional approaches, MPR and 
treatment compliance, both of which used a gap of  30 days 
to define discontinuation of medication treatment and took 
into account all medication episodes. Compared to those 
calculated by treatment persistence, results with regard to 
the levels of treatment adherence with different antipsy-
chotic agents based on MPR or treatment compliance were 
quite mixed. On the one hand, consistent with treatment 
persistence, both MPR and treatment compliance revealed 
that among the atypical agents, patients who initiated on 
clozapine were most adherent, whereas patients who were 
initiated on risperidone were least adherent; and among 
the typical agents, patients who initiated on perphenazine 
were most adherent and those initiated on haloperidol 
were least adherent. On the other hand, levels of treatment 
adherence with different antipsychotic agents tended to 
vary across the 3 existing measures. For instances, using 
treatment persistence, initiators of olanzapine and initiators 
of ziprasidone stayed on treatment for the same duration 
(151 days). However, using MPR, initiators of ziprasidone 
stayed on treatment significantly longer than initiators of 
olanzapine (269 vs 246 days; P  0.001). Similarly, using 
MPR, initiators of ziprasidone remained on treatment 
slightly longer, but statistically non-significant, than initia-
tors of quetiapine (269 vs 266 days). But, when medication 
compliance was used, initiators of quetiapine remained on 
treatment significantly longer than initiators of ziprasidone 
(191 vs 178 days; P  0.05). Such a finding was also 
observed among the typical agents, in which initiators of 
chlorpromazine remained on medication treatment slightly 
longer than initiators of haloperidol (117 vs 110 days, 
P  0.05) when measured by treatment persistence, but 
initiators of chlorpromazine remained on medication treat-
ment significantly longer than initiators of haloperidol 
(234 vs 197 days, P  0.001) when measured by MPR.
Results from Table 3 also revealed that among those with 
multiple medication episodes, the number of days patients 
remained on the index drug tended to be longer during the 
last medication episodes than during the initial medication 
episodes. For instance, among those with 2 medication 
episodes, patients remained on olanzapine for 68 days for the 
first episode, but 130 days for the second episode. Similarly, 
among those with 3 or more medication episodes, patients 
remained on olanzapine for 53 and 50 days, respectively, 
for the first and second episodes, but 96 days for the last 
episode. Furthermore, the differences in the number of days 
remaining on the index drug following initiation until a gap 
of 30 days across antipsychotic agents tended to vary 
across different medication episodes. As shown in Table 3, 
among patients with 1 medication episode, initiators of que-
tiapine had a significantly longer mean number of treatment 
days (186 days) than initiators of risperidone (168 days) 
(P  0.001). However, among those with 2 or 3 medication 
episodes, initiators of quetiapine had shorter, though statisti-
cally non-significant, mean number of treatment days during 
the first medication episodes, but had significantly longer 
mean number of treatment days than initiators of risperidone 
during the last medication episodes.
These findings highlight the need to not only incorporate 
all medication episodes but also distinguish patients with 
single vs multiple medication episodes in measuring medi-
cation adherence. Considering that the number of patients 
with multiple medication episodes tended to vary across 
antipsychotic agents, coupled with the fact that number of 
days remaining on medication treatment tended to vary across 
antipsychotic agents when different medication episodes 
were used, we developed a new, episode-specific medica-
tion adherence measure. More specifically, we compared 
medication adherence across antipsychotic agents by 
Table 2 Number of patients with multiple medication episodes
Drug name 10/1/2002 to 3/31/2005
Total 1 Episode 2 Episodes 3 + Episodes
N N % N % N %
Atypical agents
  clozapine 271 250 92.3 14 5.2 7 2.6
  Olanzapine 5,412 4,337 80.1 865 16.0 210 3.9
  Quetiapine 7,412 6,093 82.2 1,071 14.5 248 3.3
  Risperidone 7,482 6,060 81.0 1,125 15.0 297 4.0
  Ziprasidone 2,323 2,033 87.5 244 10.5 46 2.0
Typical agents
  haloperidol 2,600 2,084 80.2 421 16.2 95 3.6
  Perphenazine 414 255 80.2 51 16.0 12 3.8
  chlorpromazine 452 359 79.4 74 16.4 19 4.2Neuropsychiatric Disease and Treatment 2009:5 495
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stratifying on the number of medication episodes. As shown 
in Table 4, results based on this new approach reveal one 
general finding, ie, number of days remaining on medica-
tion treatment across different antipsychotics tended to vary 
across different medication episodes. Among the 3 typical 
agents, initiators of chlorpromazine had better medication 
adherence than initiators of haloperidol, but such differ-
ences appeared to be trivial and non-significant among those 
with 1 medication episode (131 vs 124 days), moderate 
among those with 2 medication episodes (191 vs 171 days; 
P  0.05), but strong among those with 3 medication 
episodes (195 vs 154 days; P  0.001). Among the 5 atypical 
agents, initiators of olanzapine tended to stay significantly 
longer on treatment than initiators of risperidone among those 
with 3 medication episodes (199 vs 192 days, P  0.01), 
but such a difference between the 2 agents was trivial and 
non-significant among those with 1 medication episode 
(171 vs 168 days) or 2 medication episodes (198 vs 199 days). 
Similarly, compared to initiators of quetiapine, initiators of 
ziprasidone had poorer treatment adherence among those 
with 1 medication episode (172 vs 186 days; P  0.001), but 
better treatment adherence among those with 2 medication 
episodes (222 vs 210 days; P  0.01).
Discussion and conclusions
Although a number of studies have found that poor adherence 
to medication treatment is quite common among many 
patients with schizophrenia,9–11,13,15,16 the results for the lev-
els of treatment adherence across the antipsychotic agents 
have been mixed. For instance, some studies indicated that 
the use of atypical antipsychotic agents was associated with 
significantly less medication switching than the use of typical 
antipsychotic agents,4 and that only about 11% of the patients 
with schizophrenia who were receiving typical antipsychotic 
agents achieved uninterrupted therapy, with a mean duration 
of 142 days over a year, or 39% of days covered.24 Another 
study based on the VA database, however, reported that treat-
ment persistence with atypical antipsychotic agents was only 
modestly better than that with typical antipsychotic agents25 
Other studies reported that there were no statistically sig-
nificant differences between levels of medication adherence 
to typical and atypical antipsychotic agents,12,26 with about 
44% and 48% of patients with schizophrenia continuing to 
refill their prescriptions for atypical and typical antipsychotic 
agents, respectively.3
In this study, we assessed the measurementproperties 
of the 3 commonly used, pharmacy-based measures of 
treatment adherence and found that each measure differed in 
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its approach, which might have contributed to the inconsistent 
findings across antipsychotic agents. The results of the study 
revealed 3 findings. First, as high as 24% of the patients 
with schizophrenia had 2 or more medication episodes and 
percentage patients with 2 or more medication episodes 
tended to vary across different antipsychotic agents. Because 
multiple medication episodes can either be attributed to 
patients making more switches among antipsychotic agents 
or simply being less adherent to medication treatment, 
patients with more medication episodes may therefore have 
more severe symptoms of schizophrenia. Second, mean 
number of days remaining on medication treatment across 
patients with 2 medication episodes revealed that levels of 
medication adherence were universally lower at the initial 
episode(s), but much higher at the last episodes. This find-
ing seems to indicate that the reason why patients having 
more medication episodes is largely due to switching among 
antipsychotic agents and not due to being less adherent to 
medication treatment. Patients with more severe symptoms 
are more likely to try several different antipsychotics before 
settling on the antipsychotic agent that they feel comfortable 
with. Third, number of days remaining on the medication 
treatment tended to vary across antipsychotic agents as well 
as across medication episodes. These findings highlight 
the measurement problems associated with conventional 
approach to measuring medication adherence. On the one 
hand, treatment persistence used only the first medication epi-
sode, which combined the single prescription for patients who 
had one prescription with the first episodes among patients 
who had two or three medication episodes. This approach 
excluded the second episode among patients with two medi-
cation episodes and the second and last episodes among those 
with three medication episodes. This inclusion and exclusion 
criteria associated with treatment persistence are problematic 
and the results based on the approach are likely to be biased. 
On the other hand, although medication compliance took 
into account all medication episodes, this approach had one 
drawback, that is, by lumping together patients with different 
numbers of medication episodes, one would not be able to 
capture the differences in medication adherence between 
patients with one medication episode and those with multiple 
medication episodes. This approach very much resembled 
the MPR, another commonly used measure of compliance 
with medication treatment.19,20 While medication compli-
ance considers the size of the gap, ie, 30 days, to define 
discontinuation of medication treatment, MPR does not take 
into account the size of the gap in defining discontinuation 
of medication treatment.
Recognizing that patients with 1 medication episode may 
be different from those with 2 or 3 medication episodes, we 
proposed an alternative approach in measuring medication 
adherence, ie, an episode-specific approach. This approach 
enabled us to distinguish patients with 1 medication episode 
from those with 2 or 3 medication episodes in terms of 
medication adherence. As discussed earlier, patients with 
multiple medication episodes may represent more compli-
cated cases of schizophrenia. By comparing episode-specific 
medication adherence, our new approach provides a fair 
comparison of medication adherence across antipsychotic 
agents by avoiding the potential bias against those antipsy-
chotic agents having more patients with multiple medica-
tion episodes, who present with more severe symptoms of 
schizophrenia and are more likely to switch back and forth 
among antipsychotic agents.
Table 4 Medication episode-specific treatment adherence (using a gap of 30 days as discontinuation of medication)
Drug name 10/1/2002 to 3/31/2005
1 Episode 2 Episodes 3 + Episodes
Mean ± SD N Mean ± SD N Mean ± SD N
Atypical agents
  clozapine 255 ± 146 250 234 ± 205 14 255 ± 255 6
  Olanzapine 171 ± 140 4,337 198 ± 180 865 199 ± 172 179
  Quetiapine 186 ± 144 6,093 210 ± 179 1,071 221 ± 185 218
  Risperidone 168 ± 140 6,060 199 ± 181 1,125 192 ± 161 273
  Ziprasidone 172 ± 139 2,033 222 ± 190 244 184 ± 183 42
Typical agents
  haloperidol 124 ± 128 2,084 171 ± 165 421 154 ± 136 79
  Perphenazine 169 ± 136 255 220 ± 191 51 163 ± 153 12
  chlorpromazine 131 ± 126 359 191 ± 176 74 195 ± 186 18Neuropsychiatric Disease and Treatment 2009:5 497
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It is important to note two limitations of the study. First, 
the study included predominantly male patients from the VA 
health care services. Patterns of medication adherence to vari-
ous antipsychotic agents observed in the present study may 
not be generalizable to female patients. Second, due to the 
observational nature of study, ie, without randomized assign-
ment, the results of the study may be affected by selection 
biases. Despite the fact that observational studies represent 
the spectrum of routine medical practice better than random-
ized experiments, it is important for future observational 
studies to use statistical techniques, such as propensity scores 
and sensitivity analyses, to minimize the confounding errors 
associated with observational studies. Despite the limitations, 
the results of the study have important implications for the 
care of patients with schizophrenia. With several antipsy-
chotic drugs available, physicians are increasingly confronted 
with many critical choices in selecting antipsychotic agents 
that tend to benefit the patients. Since poor medication adher-
ence contributed to an estimated 40% relapses,27 levels of 
medication adherence have become increasingly important 
in prescription choices among different antipsychotic agents. 
However, considering the inappropriateness of the conven-
tional approach in measuring medication adherence as well as 
the limitations of the present study, more research is needed 
to examine the extent to which adjunctive use of other agents, 
a common practice among patients with schizophrenia,28 
dose of treatment, and stage of illness will influence levels 
of treatment adherence. Future research should also assess 
the impact of poor treatment adherence on a wide spectrum 
of patient outcomes.29 A more comprehensive assessment 
using appropriate analytic methods should provide physi-
cians with a better knowledge about treatment adherence 
associated with different antipsychotic agents and help them 
make prescription choices that will ultimately improve the 
care of schizophrenia.
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